Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing

Citius Pharmaceuticals Regains Nasdaq Compliance

In an uplifting announcement, Citius Pharmaceuticals, Inc. has confirmed that it has regained compliance with the minimum bid price requirement set by The Nasdaq Stock Market. The company received formal notification indicating that from June 20 to July 3, 2025, its common stock maintained a closing bid price of $1.00 per share or higher for 10 consecutive trading days. This compliance means that the previously scheduled hearing with the Nasdaq Hearing Panel has been canceled, ensuring that Citius Pharmaceuticals' securities will continue to be listed and traded on the Nasdaq.

Leonard Mazur, the company's Chairman and CEO, expressed his contentment with the news, stating that this milestone reflects Citius Pharma's ongoing commitment to developing critical care products and creating enduring value for shareholders. Just over the past year, the company had been addressing concerns regarding its stock price. The ability to meet Nasdaq's criteria is critical for Citius, as the listing facilitates greater access to capital markets, benefiting ongoing research and development of innovative therapies.

Citius Pharmaceuticals specializes in biopharmaceuticals, focusing on the development and commercialization of first-in-class critical care products. Notably, in August 2024, the FDA approved LYMPHIR, a targeted immunotherapy designed for the treatment of cutaneous T-cell lymphoma. The company is also working on late-stage pipeline products, including Mino-Lok®, an antibiotic lock solution aimed at salvaging catheters for patients battling catheter-related bloodstream infections. The Halo-Lido topical formulation offers a solution for hemorrhoid relief.

In 2023, Citius Pharma successfully completed pivotal Phase 3 trials for Mino-Lok, which met both primary and secondary endpoints, showcasing the product's potential efficacy and safety. Currently, the company is actively discussing the next steps with the FDA for advancing both Mino-Lok and Halo-Lido.

Moreover, Citius Pharmaceuticals owns a majority stake (92%) in Citius Oncology, underscoring a strategic position within the oncology therapy landscape. The collaborative efforts across these projects reflect the firm’s ambition to innovate and respond to pressing health care needs through advanced biopharmaceuticals.

Citius continues to navigate the complexities of the biopharma industry, managing challenges including compliance with stringent regulatory requirements, ensuring the efficacy of their therapeutic candidates, and securing necessary financing. The road ahead is not without hurdles, yet the recent news about regaining Nasdaq compliance is a promising sign of solidifying the company's positioning within the market.

In light of ever-evolving healthcare demands, Citius Pharmaceuticals is geared toward becoming a key player in providing effective solutions for patients requiring critical care. With the support of stakeholders and a clear vision for innovation, Citius Pharma is poised to make significant contributions to the biopharmaceutical landscape.

For more detailed information about their ongoing projects, you can visit their official website at www.citiuspharma.com.